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Abstract Proteasome inhibitors were shown previously to
induce mitochondria-independent and caspase-3-dependent apo-
ptosis in human glioma cell lines by unknown mechanisms. Here,
we showed that treatment with proteasome inhibitors, lactacystin
or acetyl-leucinyl-leucinyl-norleucinal, led to elevation of the
steady-state c-Myc protein but not c-myc mRNA, suggesting the
accumulation of c-Myc protein by proteasome inhibitors. In
addition, the marked association of c-Myc protein with ubiquitin
by treatment with proteasome inhibitors indicated the involve-
ment of proteasome in c-Myc proteolysis and the stabilization of
c-Myc protein by proteasome inhibitors in vivo. The expression
of Fas (also termed CD95 or APO-1) mRNA, if analyzed by
reverse transcriptase polymerase chain reaction assay, was found
to occur constitutively, and increased slightly by the treatment
with proteasome inhibitors. In contrast, the expression of Fas
ligand (FasL) mRNA was markedly induced temporarily before
the activation of caspase-3 by the treatment. Agonistic anti-Fas
antibody (CH11) induced apoptotic cell death, suggesting the
presence of a functional Fas receptor. In addition, proteasome
inhibitor-induced apoptosis was prevented by the addition of
antagonistic anti-FasL antibody (4A5) or z-IETD.fmk, a potent
inhibitor of caspase-8, indicating the involvement of the Fas
receptor^ligand apoptotic signaling system in proteasome
inhibitor-mediated apoptosis. Thus, it is suggested that protea-
some inhibitors cause the accumulation of c-Myc protein which
induces transiently FasL message to stimulate the Fas receptor^
ligand apoptotic signaling pathway. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
In higher eukaryotic cells, the proteasome is involved in the
ATP/ubiquitin-dependent proteolysis of most of the nuclear
and cytosolic proteins and in particular of short-lived proteins
critical for cell proliferation and cell cycle regulation. The
natural product lactacystin, a speci¢c inhibitor of proteasome
[1], and acetyl-leucinyl-leucinyl-norleucinal (AcLLNal), one of
the peptide aldehyde inhibitors of proteasome, have been
shown to induce apoptotic cell death by the activation of
caspase-3 in tumor cells including human glioma cells [2^6].
In mammals, programmed cell death can be initiated by three
distinct pathways [7,8] : (i) the extrinsic pathway, which can be
triggered by ligation of death receptors, such as Fas (also
termed CD95 or APO-1), tumor necrosis factor receptor, or
TRAIL receptor, and subsequent mitochondria-independent
caspase-8 activation, which cleaves o¡ an N-terminal frag-
ment of Bid, a proapoptotic member of the Bcl-2 family, in
low caspase-8 activation, allowed by the tBid to translocate to
mitochondria and induce cytochrome c release [9,10]; (ii) the
intrinsic pathway, which is initiated by diverse apoptotic stim-
uli and converges at mitochondria to release cytochrome c
from mitochondria into cytosol followed by activation of cas-
pase-9; or (iii) the granzyme B pathway, where the cytotoxic
cell protease granzyme B is delivered to sensitive target cells.
Each of these pathways converges to a common execution
phase of apoptosis that requires the activation of caspase-3
from its inactive zymogen form to its processed, active form.
Calphostin C (a speci¢c inhibitor of protein kinase C)-in-
duced apoptosis in human glioma cell lines (U-87MG and
T98G) is associated with cytochrome c release from mitochon-
dria into cytosol and dissipation of mitochondrial potential
[11,12], indicating the presence of the intrinsic apoptotic path-
way. Nevertheless, lactacystin- or AcLLNal-induced apoptosis
in U-87MG and T98G glioma cell lines is not associated with
cytochrome c release and loss of mitochondrial potential [6],
indicating the presence of the extrinsic apoptotic pathway
which induces mitochondria-independent apoptosis in
U-87MG and T98G cell lines. In contrast, lactacystin- and
MG132 (a proteasome inhibitor)-induced apoptosis in other
human glioma cell lines (LN-18 and LN-18-R) is associated
with cytochrome c release from mitochondria and loss of mi-
tochondrial potential without any involvement of both Fas
receptor^ligand interactions and CrmA-sensitive caspase
[13]. The di¡erence in ¢ndings regarding cytochrome c release
and disruption of mitochondrial potential between two experi-
ments on human glioma cell lines might possibly be caused by
the di¡erent phenotypes and genotypes of these cell lines re-
ported recently [14]. Furthermore, proteasome inhibitor-in-
duced apoptosis in human leukemia cells [15] and cultured
rat cortical neurons [16] involves a cytochrome c-dependent
pathway, raising the possibility that the execution of apopto-
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sis induced by proteasome inhibitor is likely to be mediated,
depending upon the cell types and cellular factors, through
several mechanisms including both cytochrome c-dependent
and -independent pathways. Recently, proteasome inhibitors
have been reported to sensitize human vascular smooth
muscle cells to Fas receptor^ligand-mediated apoptotic cell
death [17]. Our data show here that proteasome inhibitors
induce the accumulation of c-Myc protein and subsequent
induction of FasL message in human glioma cell lines
U-87MG and T98G to mediate mitochondria-independent
apoptosis via the Fas receptor^ligand apoptotic pathway.
2. Materials and methods
2.1. Glioma cell culture
Two human glioma cell lines, wild-type p53-positive U-87MG and
mutant p53-positive T98G cells, were obtained from American Type
Culture Collection, Rockville, MD, USA, and were maintained in
Dulbecco’s modi¢ed Eagle’s minimum essential medium supple-
mented with 10% fetal calf serum and antibiotics in a humidi¢ed
atmosphere of 5% CO2 and 95% air at 37‡C. Cells were exposed to
50 WM lactacystin or 50 WM AcLLNal (Cosmo Bio Inc., Tokyo,
Japan) for indicated times, and were stained with 2.5 Wg/ml Hoechst
33258 after ¢xation with 4% paraformaldehyde. The number of apo-
ptotic cells was assessed based on the expression of morphological
features characteristic of apoptosis, and viability of the cells was con-
¢rmed by the trypan blue dye exclusion method.
2.2. Cell lysis, immunoprecipitation, and immunoblotting
Cells were lysed on ice in lysis mixture containing 2 mM Na3VO4,
1% Triton X-100, 1 mM ethylenediaminetetraacetic acid (EDTA), 10
Wg/ml aprotinin, 10 Wg/ml leupeptin and 1 mM phenylmethylsulfonyl
£uoride (PMSF) in phosphate-bu¡ered saline (PBS). In ubiquitin blot-
ting experiments the cells were lysed in boiling lysis bu¡er containing
1% sodium dodecylsulfate (SDS) in PBS in order to avoid isopepti-
dase activity. The lysate was heated at 100‡C for 5 min, sheared to
break DNA and centrifuged for 5 min at 10 000Ug. Immunoprecipi-
tations were carried out in 1% Triton X-100, 0.5% SDS, 0.25% so-
dium deoxycholate, 0.5% bovine serum albumin, 1 mM EDTA, 2 mM
Na3VO4, 0.1 M NaF, 10 Wg/ml leupeptin, 10 Wg/ml pepstatin, 1 mM
PMSF in PBS. The reactions were incubated for 2 h at 0‡C with anti-
c-Myc antibody and protein A-agarose (Repligen, Cambridge, MA,
USA) was used to isolate the immune complexes. The immunopreci-
pitates were washed twice with the same bu¡er and once with 10-fold
diluted PBS, and immune complexes were analyzed by 7.5% polyac-
rylamide gel electrophoresis in the presence of SDS. For immunoblot-
ting following immunoprecipitation, the immunoprecipitates obtained
with anti-c-Myc antibody were transferred to polyvinylidene di£uo-
ride membrane, and immunostained using anti-ubiquitin conjugate
antibody (FK1) [18] or anti-c-Myc antibody. In addition, levels of
c-Myc protein were probed immunologically by immunoblot analysis.
The antigens were visualized using ECL system (Amersham, UK).
2.3. RT-PCR for c-myc, Fas and FasL expression
The expression of c-myc, Fas and FasL mRNA was analyzed by
reverse transcriptase-polymerase chain reaction (RT-PCR) assay. To-
tal RNA samples were prepared with Isogen (Nippon Gene Co.,
Toyama, Japan) according to the manufacturer’s recommended pro-
tocol. For the ¢rst strand cDNA synthesis, 0.5 Wg of total RNA was
primed with oligo[dT] in reverse transcription with the AMV RNA
PCR Kit Ver. 2.1. (Takara Shuzo, Kyoto, Japan). Subsequently,
c-myc cDNA was ampli¢ed by 30 cycles of PCR with primers of 5P-
CTGGTGCTCCATGAGGAG-3P and 5P-AGGTGATCCAGACTC-
TGAC-3P, Fas cDNA was ampli¢ed by 30 cycles of PCR with primers
of 5P-TCTAACTTGGGGTGGCTTTGTCTTC-3P and 5P-GTGTCA-
TACGCTTTCTTTCCAT-3P, and FasL cDNA was ampli¢ed by 30
cycles of PCR with primers of 5P-GGATTGGGCCTGGGGAT-
GTTTCA-3P and 5P-AGCCCAGTTTCATTGATCACAAGG-3P. As
a control, glyceraldehyde phosphate dehydrogenase (GAPDH)
cDNA was ampli¢ed from the same ¢rst strand cDNA reactions,
with primers 5P-GGCGTCTTCACCACCATGGAG-3P and 5P-AAG-
TTGTCATGGAATGACCTTGG-3P (Central Laboratory, Nippon
Flour Mills, Kanagawa, Japan). The PCR products, 135-bp c-myc
fragment, 365-bp Fas fragment, 278-bp FasL fragment, and 206-bp
GAPDH fragment, were separated by electrophoresis on a 1.5 or 2.0%
agarose gel and visualized by ethidium bromide staining. PCR ampli-
¢cations were performed on a GeneAmp PCR System 2400 (Perkin-
Elmer, Norwalk, CT, USA).
3. Results
3.1. Inhibition of proteasomal activity is accompanied by
accumulation of c-Myc
Immunoreactive steady-state levels of c-Myc protein were
increased as early as 6 h after treatment with lactacystin and
8 h after treatment with AcLLNal in U-87MG cells as well as
1^3 h after treatment with lactacystin and 3 h after treatment
with AcLLNal in T98G cells (Fig. 1A,B). The c-Myc protein
up-regulation was transient in U-87MG cells: the c-Myc pro-
tein levels were returned to normal at 24 h after lactacystin
treatment and at 32 h after AcLLNal treatment. The increase
in c-Myc protein levels in T98G cells was ¢xed uniformly for
at least 15 h after treatment with lactacystin or AcLLNal.
Recent evidence has indicated that the ubiquitin proteolytic
system plays a major role in targeting short-lived key regula-
tory proteins for degradation [19^21], and degradation of a
protein by means of the ubiquitin system involves two discrete
steps, conjugation of multiple molecules of ubiquitin to the
target protein and degradation of the tagged substrate by the
26S proteasome. Since the degradation of c-Myc protein in
vitro and in vivo is reported to be mediated by the ubiquitin
system [22,23], we examined the possible involvement of the
proteasome in c-Myc proteolysis of U-87MG and T98G cells
in vivo. Addition of the proteasome inhibitor led to accumu-
lation of high-molecular-mass derivatives in c-Myc immuno-
precipitates, and immunoblot analysis with anti-ubiquitin
antibody showed that these compounds were composed of
c-Myc protein^ubiquitin complexes (Fig. 1B), suggesting
that c-Myc protein is proteolysed by proteasomes and stabi-
lized by proteasome inhibition. In contrast, there was no evi-
dence of any changes of c-myc mRNA expression in U-87MG
and T98G cells assessed by RT-PCR analysis during the
c-Myc protein up-regulation induced by the proteasome in-
hibitor (Fig. 1C). Thus, it is suggested that c-Myc protein in
vivo is degraded by proteasomes and that proteasome inhib-
itors are shown to induce stabilization and accumulation of
c-Myc protein, which has an extremely short half-life of about
30 min [24].
3.2. Fas receptor is constitutively expressed
To de¢ne the cell surface expression of Fas receptor, we
analyzed the expression of Fas mRNA in U-87MG and
T98G cells by RT-PCR assay. As shown in Fig. 2A, the ex-
pression of Fas mRNA was detected before and during lacta-
cystin or AcLLNal treatment in U-87MG and T98G cells,
suggesting that both glioma cells constitutively express Fas
receptor. There was a slight enhancement of Fas mRNA lev-
els, without any signi¢cant di¡erences, concurrently with the
increase in c-Myc protein levels by treatment with either pro-
teasome inhibitor in both cells. To functionally assess the Fas
receptor expression on cells we performed a cytotoxic assay
using an agonistic anti-Fas monoclonal antibody (CH11). Ag-
onistic stimulation with anti-Fas antibody induced apoptotic
cell death as shown in Fig. 2B, suggestive of the presence of a
functional Fas receptor in human glioma cells.
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3.3. Inhibition of proteasomal activity enhances FasL mRNA
E¡ects of lactacystin or AcLLNal on the expression of
FasL mRNA were analyzed by RT-PCR assay. As shown
in Fig. 2A, the expression of FasL mRNA in U-87MG
and T98G cells was not detected before lactacystin or
AcLLNal treatment but markedly induced transiently
after the treatment. The induction of FasL mRNA was
detected 6^9 h in U-87MG cells and 2 h in T98G cells
after lactacystin treatment and 12^16 h in U-87MG cells
and 3^6 h in T98G cells after AcLLNal treatment. There-
fore, the induction of FasL message by treatment with lacta-
cystin or AcLLNal was detected concurrently with or after
the increase of c-Myc protein levels in U-87MG and T98G
cells.
Fig. 1. E¡ects of lactacystin and AcLLNal on the steady-state level of c-Myc, on the formation of c-Myc^ubiquitin conjugates, and on c-myc
mRNA expression. A: Human glioma cell lines (U-87MG and T98G) were exposed to 50 WM lactacystin or 50 WM AcLLNal for the indicated
times. Steady-state level of c-Myc protein in U-87MG and T98G cells was monitored by immunoblot analysis. B: After treatment with 50 WM
lactacystin for 6 h in U-87MG cells and for 3 h in T98G cells, lysates of both cells were immunoprecipitated with anti-c-Myc antibody (lanes
1, 2, 4, and 5) or isotypic IgG1 (lanes 3 and 6). Immunoprecipitates were resolved by means of SDS polyacrylamide gel electrophoresis, and
following transfer of the proteins to polyvinylidene di£uoride membrane the conjugates were detected by anti-c-Myc antibody (left) or anti-
ubiquitin antibody (right). c-Myc protein in U-87MG and T98G cells was increased by treatment with lactacystin (left). Adducts of c-Myc pro-
tein with ubiquitin were accumulated by treatment with lactacystin (right). IP, immunoprecipitation; IB, immunoblot; Ub, ubiquitin; 1^3,
U-87MG; 4^6, T98G; 2 and 5, treatment with lactacystin; 1 and 4, no treatment. C: c-myc mRNA expression was analyzed by RT-PCR per-
formed on total RNA isolated from U-87MG and T98G cells after treatment with lactacystin for the indicated times. A 206-bp GAPDH frag-
ment was used to control for equal amounts of cDNA synthesized in the RT reactions. The results are from a representative study performed
three times with comparable outcomes.
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3.4. Fas receptor^ligand system is involved in proteasome
inhibitor-induced apoptosis
To directly analyze whether the Fas receptor^ligand apo-
ptotic pathway is involved in proteasome inhibitor-mediated
apoptosis, we employed 10 Wg/ml antagonistic anti-FasL anti-
body (4A5), which interferes with the Fas receptor^ligand
interaction. If added to the culture medium 60 min prior to
the treatment with lactacystin or AcLLNal, 4A5 antibody
prevented the proteasome inhibitor-induced apoptotic cell
death of U-87MG and T98G cells as shown in Fig. 3A. In
addition, to analyze whether the Fas receptor^ligand apopto-
tic pathway has a direct role in proteasome inhibitor-induced
cell death of U-87MG and T98G cells, we investigated the
e¡ects of 20 WM z-IETD.fmk, a potent inhibitor of caspase-
8, on proteasome inhibitor-mediated cellular responses by
adding it to the culture medium 60 min prior to the treatment
with lactacystin or AcLLNal. Z-IETD.fmk prevented the pro-
teasome inhibitor-mediated cell death (Fig. 3B) and morpho-
logical features characteristic of apoptosis (Fig. 3C), such as
cell shrinkage and surface blebbing by phase contrast images
as well as nuclear condensation and fragmentation by Hoechst
33258 stain.
4. Discussion
The degradation of c-Myc protein in vitro [22] and in vivo
[23] has been reported to be mediated by the ubiquitin system.
The present study clearly demonstrates that lactacystin or
AcLLNal induces the stabilization and accumulation of
c-Myc protein through the inhibition of the ubiquitin proteo-
lytic system. The inhibition of proteasome activity is reported
to cause accumulation of the c-Myc protein and induces ap-
optosis of preferentially c-myc-transformed ¢broblasts and
lymphoblasts [25]. In addition, the reduction of proteasome
inhibitor-induced apoptosis by protein synthesis inhibitor was
reported previously [6], suggesting that the accumulation of
short-lived proteins such as c-Myc protein is associated with
proteasome inhibitor-mediated apoptosis. Recently, Bax has
been reported to be a direct transcriptional target of c-Myc
and contributes to c-Myc-induced apoptosis [26], but Bax
protein levels in U-87MG and T98G cells were not changed
by the treatment with lactacystin or AcLLNal [6].
Fas mRNA was constitutively expressed, and the Fas mes-
sage, when analyzed by RT-PCR assay, was slightly increased
concurrently with the enhancement of c-Myc protein by the
treatment with lactacystin or AcLLNal. Recently, proteasome
inhibitors have been reported to up-regulate Fas of human
vascular smooth muscle cells [17], and the interaction of Fas
with the ubiquitin-conjugating enzyme [27,28] may be directly
involved in ubiquitin-dependent degradation of Fas by pro-
teasome. However, nothing is known on possible ubiquitina-
tion or stability of Fas. In contrast, the expression of FasL
mRNA was markedly induced transiently by the treatment
with lactacystin or AcLLNal, and the induction of FasL mes-
sage was detected concurrently with or after the increase of
c-Myc protein levels, suggesting that c-Myc protein plays a
fundamental role in the regulation of the expression of FasL
but not Fas as reported in T cells [29,30]. In addition, Brunner
et al. [30] have reported recently that FasL promoter activity
in T cells is driven by overexpression of c-Myc protein and
inhibited by expression of dominant negative mutants of
c-Myc. Since the activation of caspase-3 was detected as early
as 18 h after lactacystin treatment and 24 h after AcLLNal
treatment in U-87MG cells and as early as 9 h after lactacys-
tin or AcLLNal treatment in T98G cells [6], both the increase
of c-Myc protein levels and the induction of FasL message
occur before the activation of caspase-3.
Fas and FasL expression is reported in human glioma cells
[31^36] and a signi¢cant number of gliomas co-express both
Fas and FasL [31,32,36]. Agonistic anti-Fas antibody (CH11)
induced the apoptotic cell death in the present and other
human glioma cells [37], suggesting the presence of a func-
tional Fas receptor and an intact Fas apoptotic signaling
pathway in the present glioma cell lines. In addition, protea-
some inhibitor-induced apoptosis was prevented by addition
of antagonistic anti-FasL antibody (4A5), which neutralizes
FasL. Thus, both the apoptotic e¡ects of the agonistic anti-
Fas antibody and the apoptosis-inhibiting e¡ects of the antag-
onistic anti-FasL antibody indicate the involvement of Fas
receptor^ligand interactions in the proteasome inhibitor-medi-
Fig. 2. Sensitivity of human glioma cells to Fas-mediated apoptosis.
A: Analysis of Fas and FasL mRNA expression was performed by
RT-PCR on total RNA isolated from U-87MG and T98G cells
treated with 50 WM lactacystin or 50 WM AcLLNal for the indicated
times. A 206-bp GAPDH fragment was used to control for equal
amounts of cDNA synthesized in the RT reactions. B: Fas killing
was triggered by the addition of agonistic anti-Fas antibody (CH11)
at various concentrations to T98G cells and cumulative cell death is
shown plotted against time. Open squares, treatment with mouse
isotypic IgG as control antibody; open diamonds, treatment with
0.5 Wg/ml CH11; closed circles, treatment with 1.0 Wg/ml CH11;
open triangles, treatment with 2.0 Wg/ml CH11. Similar results were
achieved in three separate experiments.
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ated apoptotic pathway. A functional relation between c-myc
and Fas apoptotic signaling was already reported in activa-
tion-induced T cell death [22,38,39]. Recently, c-Myc-induced
apoptosis in ¢broblasts and T cells has been shown to require
the Fas receptor^ligand apoptotic pathway [29,30,40].
The assembly of the Fas receptor death-inducing signaling
complex occurs in a hierarchical manner: the death domain of
Fas binds to the corresponding domain in the adapter mole-
cule Fas-associated death domain FADD, which in turn re-
cruits the zymogen form of caspase-8 by a homophilic inter-
action involving the death e¡ector domains [41^44].
Immediately after recruitment, the single polypeptide cas-
pase-8 zymogen is proteolytically processed to the active di-
meric species composed of large and small catalytic subunits
Fig. 3. E¡ects of antagonistic anti-FasL antibody (4A5: A) and caspase-8 inhibitor (z-IETD.fmk: B) on proteasome inhibitor-induced cell
death. 4A5 (10 Wg/ml) or z-IETD.fmk (20 WM) was added to the culture medium 1 h prior to the addition of 50 WM lactacystin or 50 WM
AcLLNal, and thereafter 4A5 or z-IETD.fmk was given every 12 h. After treatment with lactacystin or AcLLNal for the indicated times,
U-87MG and T98G cells were subjected to examination of cell viability. A: Open squares, no treatment; closed squares, treatment with mouse
isotypic IgG as control antibody; closed circles, treatment with 50 WM lactacystin; open circles, treatment with 50 WM lactacystin and 10 Wg/ml
4A5; closed triangles, treatment with 50 WM AcLLNal; open triangles, treatment with 50 WM AcLLNal and 10 Wg/ml 4A5. B: Open squares,
treatment with 0.1% DMSO as control; closed circles, treatment with 50 WM lactacystin; open circles, treatment with 50 WM lactacystin and 20
WM z-IETD.fmk; closed triangles, treatment with 50 WM AcLLNal; open triangles, treatment with 50 WM AcLLNal and 20 WM z-IETD.fmk.
C: Representative photomicrographs of phase contrast images and Hoechst 33258 stain of T98G cells treated with 50 WM AcLLNal for 24 h
in the absence or the presence of 20 WM z-IETD.fmk. Phase contrast was U100; Hoechst 33258 stain was U100. The data shown were ob-
tained from three separate experiments.
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that amplify the apoptotic signal by activating other down-
stream caspases such as caspase-3 [45^48]. Studies with cells
derived from caspase-8 knock-out mice indicate that caspase-8
is absolutely required for Fas receptor-induced apoptosis [49].
Thus, caspase-8 is the most apical caspase in Fas-induced
apoptosis [41,42]. Proteasome inhibitor-induced apoptosis
was prevented by the addition of z-IETD.fmk, a potent in-
hibitor of caspase-8, indicating that e⁄cient proteasome in-
hibitor-induced apoptosis requires cell surface interaction be-
tween Fas receptor and its ligand FasL and subsequent
processing of caspase-8 through FADD. Recently, protea-
some inhibitors have been shown to sensitize human vascular
smooth muscle cells to Fas receptor^ligand-mediated apopto-
tic cell death [17]. In contrast, lactacystin has been reported
recently to overcome Fas resistance in T cell leukemia cell
lines by bypassing the proximal part of the Fas signal to
activate caspase-8 [50]. However, the present study shows
that antagonistic FasL antibody prevents proteasome inhibi-
tor-induced apoptosis and agonistic Fas antibody induces
apoptotic cell death, suggesting that Fas receptor^ligand in-
teraction is necessary for proteasome inhibitor-induced apo-
ptosis in the present human glioma cell lines. The absence of
evidence of cytochrome c release from mitochondria into
cytosol in the present proteasome inhibitor-induced apoptosis
[6] indicates that cleavage of Bid by active caspase-8 [9,10]
does not occur. In conclusion, the proteasome inhibitor-in-
duced apoptosis in the present human glioma cell lines is
mediated via the Fas receptor^ligand apoptotic pathway by
the accumulation of c-Myc protein and subsequent induction
of FasL message.
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